drugset
drugset / Trial / NCT06009029

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

NCT06009029 ↗

Phase 2 Not yet recruiting 96 enrolled Peking University Third Hospital
NaSingle-groupOpen-labelTreatment

Summary

This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).

Timeline

Start
2023-08
Primary completion
2026-07
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Zimberelimab Monoclonal antibody 240 mg Intravenous

Indications

pancreatic neoplasm